The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cancer and systemic inflammation: treat the tumour and treat the host
Open accessAbstract
Determinants of cancer progression and survival are multifactorial and host responses are increasingly appreciated to have a major role. Indeed, the development and maintenance of a systemic inflammatory response has been consistently observed to confer poorer outcome, in both early and advanced stage disease. For patients, cancer-associated symptoms are of particular importance resulting in a marked impact on day-to-day quality of life and are also associated with poorer outcome. These symptoms are now recognised to cluster with one another with anorexia, weight loss and physical function forming a recognised cluster whereas fatigue, pain and depression forming another. Importantly, it has become apparent that these symptom clusters are associated with presence of a systemic inflammatory response in the patient with cancer. Given the understanding of the above, there is now a need to intervene to moderate systemic inflammatory responses, where present. In this context the rationale for therapeutic intervention using nonselective anti-inflammatory agents is clear and compelling and likely to become a part of routine clinical practice in the near future. The published literature on therapeutic intervention using anti-inflammatory agents for cancer-associated symptoms was reviewed. There are important parallels with the development of useful treatments for the systemic inflammatory response in patients with rheumatological disease and cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734 · cited 2×
“Although activation of the systemic inflammatory response involves many organ systems, the usual clinical laboratory measures of the magnitude of activation are circulating white cells and acute phase proteins (Gabay and Kushner, 1999).”
BackgroundRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Guthrie, G. J. K., Charles, K. A., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Clarke, S. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.010 · Cited by 1,552
Self-citationMcMillan, D. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.003 · Cited by 1,398
Self-citationRoxburgh, C. S., & McMillan, D. C. (2010) · Future Oncology · doi:10.2217/fon.09.136 · Cited by 998
Self-citationAnti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 843
Cited by
Cancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193
Self-citationESPEN expert group recommendations for action against cancer-related malnutrition
Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P. C., Deutz, N. E. P., Erickson, N., Laviano, A., Lisanti, M. P., Lobo, D. N., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.06.017 · Cited by 1,305
Self-citationPharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Tanaka, K., Fushiya, N., Koike, K., Nishino, H., & Matsushima, M. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4048-0 · Cited by 442
Influence of body composition profile on outcomes following colorectal cancer surgery
Malietzis, G., Currie, A. C., Athanasiou, T., Johns, N., Anyamene, N., Glynne-Jones, R., Kennedy, R. H., Fearon, K. C. H., & Jenkins, J. T. (2016) · British Journal of Surgery · doi:10.1002/bjs.10075 · Cited by 299
Shay, J., Elbaz, H. A., Lee, I., Zielske, S. P., Malek, M. H., & Hüttemann, M. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/181260 · Cited by 279
Human neutrophils in the saga of cellular heterogeneity: insights and open questions
Scapini, P., Marini, O., Tecchio, C., & Cassatella, M. A. (2016) · Immunological Reviews · doi:10.1111/imr.12448 · Cited by 274
Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance
Tuomisto, A. E., Mäkinen, M. J., & Väyrynen, J. P. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i31.4383 · Cited by 271
Systemic Inflammation Predicts All-Cause Mortality: A Glasgow Inflammation Outcome Study
Proctor, M. J., McMillan, D. C., Horgan, P. G., Fletcher, C. D., Talwar, D., & Morrison, D. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116206 · Cited by 168
“association between the systemic inflammatory response and cancer mortality, when compared with cardiovascular and cerebrovascular mortality, is not clear but highlights the potential of the systemic inflammatory response as a therapeutic oncological target [23,24].”
BackgroundSelf-citationGuo, J., Chen, S., Chen, Y., Li, S., & Xu, D. (2018) · Cancer Management and Research · doi:10.2147/cmar.s156071 · Cited by 54
Wang, Y., Booth, B., Rahman, A., Kim, G., Huang, S., & Zineh, I. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.628 · Cited by 48
Metadata
- Authors
- Roxburgh, C. S. D., & McMillan, D. C.
- Venue
- British Journal of Cancer
- Published
- 2014-02-18
- Volume
- 110
- Issue
- 6
- Pages
- 1409-1412
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2131193892
- Cited by
- 368
- References
- 32
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.